Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kestra Medical Technologies (KMTS) Research & Development (2024 - 2026)

Kestra Medical Technologies (KMTS) has disclosed Research & Development for 2 consecutive years, with $4.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development rose 39.01% to $4.9 million in Q4 2025 year-over-year; TTM through Oct 2025 was $17.6 million, a N/A change, with the full-year FY2025 number at $15.7 million, up 1.05% from a year prior.
  • Research & Development was $4.9 million for Q4 2025 at Kestra Medical Technologies, up from $4.0 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $5.4 million in Q2 2025 to a low of $3.4 million in Q1 2025.